Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observation of Anti-vascular Endothelial Growth Factor Therapy in Exudative Age-related Macular Degeneration, Proliferative Diabetic Retinopathy, Macular Edema, and Choroidal Neovascularization.

NCT05222633 is registered in ClinicalTrials.gov with Wenbin Wei as lead sponsor.

NCT NCT05222633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05222633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observation of Anti-vascular Endothelial Growth Factor Therapy in Exudative Age-related Macular Degeneration, Proliferative Diabetic Retinopathy, Macular Edema, and Choroidal Neovascularization.
Lead sponsor
Wenbin Wei
Phase
Observational
Overall status
Unknown status
Start date
January 1, 2022
Completion date
May 1, 2023
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

choroidal neovascular membrane, diabetic macular edema, neovascular age-related macular edema, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, retinal vein occlusion